19:32:16 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Bio-Works Technologies är verksamma inom bioteknik. Bolaget utvecklar produkter som separerar och renar molekyler vid framställning av läkemedel. Teknologin baseras på kromatografi som har som avsikt att hantera läkemedelssubstansen. Kunderna återfinns inom den europeiska marknaden där produkterna säljs via distributionspartners och till bolag inom läkemedelsindustrin, samt forskningsinstitut och universitet. Bolaget bildades 2006 och har sitt huvudkontor i Uppsala.


2023-02-17 Bokslutskommuniké 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-20 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-24 Ordinarie utdelning BIOWKS 0.00 SEK
2021-05-21 Årsstämma 2021
2021-02-19 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-18 Ordinarie utdelning BIOWKS 0.00 SEK
2020-05-15 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-10-18 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-27 Ordinarie utdelning BIOWKS 0.00 SEK
2019-05-17 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-08-19 Kvartalsrapport 2018-Q2
2018-05-21 Ordinarie utdelning BIOWKS 0.00 SEK
2018-05-18 Årsstämma 2018
2018-02-19 Bokslutskommuniké 2017
2020-11-16 09:00:00

As a response to the COVID-19 outbreak in the spring of this year, Bio-Works offered to help by providing resins for vaccine purification research. One such project has now resulted in a neutralizing monoclonal antibody candidate against SARS-CoV-2 being produced for clinical phase 1 testing.

More than 10 companies took advantage of Bio-Works' offer of WorkBeads resins and expert advice to help speed up vaccine or treatment development against COVID-19. One of these was Yumab, a Contract Research Organization (CRO) working in a consortium together with Boehringer Ingelheim.

Bio-Works provided WorkBeads[TM] Protein A to enable Yumab to perform screening of over one hundred antibody candidates.

Yumab has been using the WorkBeads[ ]Protein A during the past six months and has now selected one final candidate which is now in production for use in clinical Phase I testing, expected to start in January-February 2021.

"Bio-Works is extremely happy and proud to play a small part in this successful screening and to contribute in general to fighting the viral pandemic," said Jonathan Royce, CEO for Bio-Works.

André Frenzel, CSO Yumab, said: "Bio-Works has been a great help by providing the purification resin. It enabled Yumab to quickly start the screening process, efficiently screen antibody candidates and select a final candidate within just a few months."

Royce continued by saying "Our WorkBeads resin provides high purity and high binding capacity, and can be used at high flow rates to minimize process time. It's gratifying to be able to apply these advantages in such a tangible way to develop vaccines and treatments to fight COVID-19 where speed and efficiency are critical".